<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Activated protein C (APC), a protease with <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> and cytoprotective activities, protects neurons and endothelium from ischemic injury </plain></SENT>
<SENT sid="1" pm="."><plain>Drotrecogin-alfa activated, a hyperanticoagulant form of human recombinant APC, is currently being studied in patients with <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>How changes in APC <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> activity influence APC's neuroprotection and risk for <z:mp ids='MP_0001914'>bleeding</z:mp> is not clear </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We used neuronal and brain endothelial cell injury models and middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in mice to compare efficacy and safety of drotrecogin-alfa activated and human 3K3A-APC, an APC nonanticoagulant mutant </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Drotrecogin-alfa activated and 3K3A-APC exhibited 148% and 10% of plasma-derived APC's <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> activity and differ in the carbohydrate content </plain></SENT>
<SENT sid="5" pm="."><plain>3K3A-APC protected mouse neurons from N-<z:chebi fb="36" ids="29309">methyl</z:chebi>-d-<z:chebi fb="0" ids="29995">aspartate</z:chebi>-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and human brain endothelial cell from oxygen-<z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation with 1.8- and 3.1-fold greater efficacy than drotrecogin-alfa activated </plain></SENT>
<SENT sid="6" pm="."><plain>Given 5 minutes before transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, 3K3A-APC and drotrecogin-alfa activated (0.5 and 2 mg/kg intravenously) reduced comparably and dose-dependently the infarction lesion up to 85% </plain></SENT>
<SENT sid="7" pm="."><plain>3K3A-APC, but not drotrecogin-alfa activated, improved neurological score dose-dependently (P&lt;0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>3K3A-APC did not cause <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>In contrast, drotrecogin-alfa activated dose-dependently <z:hpo ids='HP_0001900'>increased hemoglobin</z:hpo> content in postischemic brain </plain></SENT>
<SENT sid="10" pm="."><plain>After permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, 3K3A-APC multidose therapy (1 mg/kg intravenously at 12 hours and 1, 3, 5, and 7 days) improved functional recovery and reduced infarction by 60% with no risk for <z:mp ids='MP_0001914'>bleeding</z:mp>, whereas drotrecogin-alfa activated <z:hpo ids='HP_0001900'>increased hemoglobin</z:hpo> deposition in the postischemic brain and showed relatively modest neuroprotection </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Nonanticoagulant 3K3A-APC exhibits greater neuroprotective efficacy with no risk for <z:mp ids='MP_0001914'>bleeding</z:mp> compared with drotrecogin-alfa activated, a hyperanticoagulant form of APC </plain></SENT>
</text></document>